Chinese english Germany Japanese Korea

Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer.

Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer. Struktur
CAS-Nr.
Englisch Name:
Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer.
Synonyma:
Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer.
CBNumber:
CB621461363
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file
Request For Quotation

Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer. Eigenschaften

Sicherheit

Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer. Chemische Eigenschaften,Einsatz,Produktion Methoden

Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer. Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer. Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 1)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Guangzhou Fu'erbo Biological Technology Co.,Ltd. 19513720913
 1536198927@qq.com China 10000 58
  • Stop providing for the issue quaI itY controI . (pIease cont us for more information) poorIY differentiated human squamous ceII carcinoma fr esophageaI cancer.
Copyright 2019 © ChemicalBook. All rights reserved